Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Poor social support and loneliness in chronic headache: Prevalence and effect modifiers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Reply: The role of neurovascular contact in patients with multiple sclerosis

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  1. Paracetamol use during pregnancy - a call for precautionary action

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. The chronobiology of migraine: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Poor social support and loneliness in chronic headache: Prevalence and effect modifiers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Health-related quality of life in tension-type headache: a population-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Cristina Tassorelli
  • Hans-Christoph Diener
  • Stephen D Silberstein
  • David W Dodick
  • Peter J Goadsby
  • Rigmor H Jensen
  • Delphine Magis
  • Patricia Pozo-Rosich
  • Hsiangkuo Yuan
  • Daniele Martinelli
  • Thomas van den Hoek
  • Marie Deen
  • Messoud Ashina
  • Gisela M Terwindt
Vis graf over relationer

BACKGROUND: Although the European Medicines Agency and the US Food and Drug Administration have cleared several devices that use neuromodulation to provide clinical benefits in the acute or preventive treatment of migraine, the Clinical Trials Committee of the International Headache Society has not developed guidelines specifically for clinical trials of neuromodulation devices. In recognition of the distinct needs and challenges associated with their assessment in controlled trials, the Committee provides these recommendations for optimizing the design and conduct of controlled trials of neuromodulation devices for the acute and/or preventive treatment of migraine.

METHODS: An international group of headache scientists and clinicians with expertise in neuromodulation evaluated clinical trials involving neuromodulation devices that have been published since 2000. The Clinical Trials Committee incorporated findings from this expert analysis into a new guideline for clinical trials of neuromodulation devices for the treatment of migraine.

RESULTS: Key terms were defined and recommendations provided relative to the assessment of neuromodulation devices for acute treatment in adults, preventive treatment in adults, and acute and preventive treatment in children and adolescents. Ethical and administrative responsibilities were outlined, and a bibliography of previous research involving neuromodulation devices was created.

CONCLUSIONS: Adoption of these recommendations will improve the quality of evidence regarding this important area in migraine treatment.

OriginalsprogEngelsk
TidsskriftCephalalgia : an international journal of headache
Vol/bind41
Udgave nummer11-12
Sider (fra-til)1135-1151
Antal sider17
ISSN0333-1024
DOI
StatusUdgivet - okt. 2021

ID: 65607140